Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMDZ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,392
Award facts
- Contract value 100% obligated
- $11,392.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11.4K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. The delivery order, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. DMS Pharmaceutical Group is performing work at its Park Ridge facility and will deliver this biologic immunosuppressant medication to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical consumables sourcing for military healthcare facilities worldwide. The PPV-G GEN V contract, awarded November 13, 2025, establishes a 30-month base period with three optional 30-month extensions through December 31, 2036, and positions DMS Pharmaceutical Group as a critical regional prime vendor contractor. The contractor's demonstrated performance across a diverse pharmaceutical portfolio—including specialty biologics, oncology treatments, vaccines, and routine medications—supports the Defense Logistics Agency's objective of ensuring reliable pharmaceutical supply chain operations for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMDZ5?
SPE2DR26FMDZ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FMDZ5 worth?
The government has obligated $11,392 on SPE2DR26FMDZ5.
Is contract SPE2DR26FMDZ5 an order under another contract?
Yes. SPE2DR26FMDZ5 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDZ5 competed?
The extent of competition for SPE2DR26FMDZ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award